Cytek Biosciences Inc CTKB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTKB is a good fit for your portfolio.
News
-
Cytek® Biosciences Names William McCombe Chief Financial Officer
-
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
-
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
-
Cytek Biosciences to Participate in Upcoming Investor Conferences
-
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Trading Information
- Previous Close Price
- $5.81
- Day Range
- $5.65–5.81
- 52-Week Range
- $3.80–12.31
- Bid/Ask
- $5.65 / $5.66
- Market Cap
- $740.46 Mil
- Volume/Avg
- 477,762 / 718,472
Key Statistics
- Price/Earnings (Normalized)
- 134.95
- Price/Sales
- 4.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 5.81%
Company Profile
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 676
- Website
- https://www.cytekbio.com
Comparables
Valuation
|
Metric
|
CTKB
|
TIHE
|
688468
|
|---|---|---|---|
Price/Earnings (Normalized) | 134.95 | — | 19.20 |
Price/Book Value | 1.93 | — | 1.99 |
Price/Sales | 4.07 | — | 5.94 |
Price/Cash Flow | 49.78 | — | 15.70 |
Price/Earnings
CTKB
TIHE
688468
Financial Strength
|
Metric
|
CTKB
|
TIHE
|
688468
|
|---|---|---|---|
Quick Ratio | 5.67 | — | 4.85 |
Current Ratio | 6.97 | — | 5.74 |
Interest Coverage | −9.68 | — | 644.72 |
Quick Ratio
CTKB
TIHE
688468
Profitability
|
Metric
|
CTKB
|
TIHE
|
688468
|
|---|---|---|---|
Return on Assets (Normalized) | −0.05% | — | 7.84% |
Return on Equity (Normalized) | −0.06% | — | 9.23% |
Return on Invested Capital (Normalized) | −0.83% | — | 8.57% |
Return on Assets
CTKB
TIHE
688468
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Pbmdbqdm | Qvxqnv | $185.8 Bil | |
SYK
| Stryker Corp | Hzlrjhtpv | Vsvbd | $127.4 Bil | |
MDT
| Medtronic PLC | Qxhxlnvl | Kkttk | $105.2 Bil | |
BSX
| Boston Scientific Corp | Dhbytnxjh | Pbzldz | $99.0 Bil | |
DXCM
| DexCom Inc | Brrggbbsry | Pngp | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Bcdpzpgscb | Cnpfcy | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Ddlrrymxyf | Mnwd | $25.0 Bil | |
ALGN
| Align Technology Inc | Jyjcbcbdg | Zdmcnt | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Dkmbvdyph | Cjghrcj | $18.9 Bil | |
PODD
| Insulet Corp | Dsmqyggt | Qctgh | $11.7 Bil |